TP53 mutations sensitize to decitabine

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

BACKGROUND The molecular determinants of clinical responses to decitabine therapy in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) are unclear. METHODS We enrolled 84 adult patients with AML or MDS in a single-institution trial of decitabine to identify somatic mutations and their relationships to clinical responses. Decitabine was administered at a dose of 20 ...

ADAMTS16 mutations sensitize ovarian cancer cells to platinum-based chemotherapy

Ovarian cancer is one of the most lethal malignant tumors in women. The prognosis of ovarian cancer patients depends, in part, on their response to platinum-based chemotherapy. Our recent analysis of genomics and clinical data from the Cancer Genome Atlas demonstrated that somatic mutations of ADAMTS 1, 6, 8, 9, 15, 16, 18 and L1 genes were associated with higher sensitivity to platinum and lon...

TP53 mutations in workers exposed to occupational carcinogens.

In some cases, evidence exists that exogenous carcinogenic exposures contribute to the mutation spectrum of the TP53 gene (p53) in human cancers. Although the clearest examples come from dietary and environmental sources, only a restricted number of papers have concentrated specifically on TP53 mutations in tumors from workers exposed to occupational carcinogens. In populations exposed to dieta...

Letter to BLOOD Acute myeloid leukemia with TP53 germline mutations

TP53 mutations on circulating cell-free DNA

Article history: Received 6 July 2016 Accepted 6 July 2016 Available online 8 July 2016 Besides the demand for higher sensitivity, the specificity of cfDNA measurements faces even more serious challenges. Cancer-associated mutations are thought to be restricted to cancer patients. However, Fernandez-Cuesta et al. observed cfDNA TP53-mutated fragments in 11.4% of 123 matched non-cancer controls....